sellWeak cluster of 410b5-1 plan
Brian DeSchuytner sold $4,913 of MRSN
SVP, COO & CFO at Mersana Therapeutics, Inc.. 8,470 shares at an average of $0.58, traded Jan 16, 2025, filed Jan 17, 2025.
Warning score
2Value
$4,913
8,470 shares
Holdings after
121,393
-7% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- 0Trade size$5k at market
- 0Share of holdings soldSold 6.5% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-25-004592, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 15, 2025 | MOption exercise Common Stock10b5-1 | +6,250 | $0.00 | $0 | 115,280 | Jan 17, 2025 |
| Jan 15, 2025 | MOption exercise Common Stock10b5-1 | +14,583 | $0.00 | $0 | 129,863 | Jan 17, 2025 |
| Jan 16, 2025 | SOpen-market sale Common Stock10b5-1 | -8,470 | $0.58 | $4,913 | 121,393 | Jan 17, 2025 |
| Jan 15, 2025 | MOption exercise Restricted Stock Unitderivative10b5-1 | -6,250 | $0.00 | $0 | 0 | Jan 17, 2025 |
| Jan 15, 2025 | MOption exercise Restricted Stock Unitderivative10b5-1 | -14,583 | $0.00 | $0 | 43,750 | Jan 17, 2025 |
| Jan 15, 2025 | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +281,250 | $0.00 | $0 | 281,250 | Jan 17, 2025 |
| Jan 15, 2025 | AGrant or award Restricted Stock Unitderivative10b5-1 | +62,500 | $0.00 | $0 | 62,500 | Jan 17, 2025 |
Related signals
Other insiders at Mersana Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Mersana Therapeutics, Inc. | Mohan Bala SVP, Chief Development Officer | $762 77 shares | -3% | |
| 0Weak | Mersana Therapeutics, Inc. | Martin H. Huber Jr. President, CEO | $15k 2,012 shares | -17% | |
| 0Weak | Mersana Therapeutics, Inc. | Mohan Bala SVP, Chief Development Officer | $3,445 5,939 shares | -8% | |
| 0Weak | Mersana Therapeutics, Inc. | Alejandra Carvajal SVP, Chief Legal Officer | $2,956 5,096 shares | -6% | |
| 5Weak | Mersana Therapeutics, Inc. | Martin H. Huber Jr. President, CEO | $2,618 4,514 shares | -4% | |
| 0Weak | Mersana Therapeutics, Inc. | Alejandra Carvajal SVP, Chief Legal Officer | $600 952 shares | -1% | |
| 2Weak | Mersana Therapeutics, Inc. | Brian DeSchuytner SVP, COO & CFO | $1,469 2,331 shares | -2% | |
| 0Weak | Mersana Therapeutics, Inc. | Mohan Bala SVP, Chief Development Officer | $2,147 3,253 shares | -5% | |
| 0Weak | Mersana Therapeutics, Inc. | Alejandra Carvajal SVP, Chief Legal Officer | $2,198 3,330 shares | -5% | |
| 2Weak | Mersana Therapeutics, Inc. | Brian DeSchuytner SVP, COO & CFO | $2,451 3,713 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.